NeoTX

Immuno-oncology Drug Development

Active C Startup Rehovot Founded 2015-04

Website ↗ LinkedIn

NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The technology…